scholarly journals Associations of Circulating Irisin with FNDC5 Expression in Fat and Muscle in Type 1 and Type 2 Diabetic Mice

Biomolecules ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 322
Author(s):  
Songling Jiang ◽  
Lingjuan Piao ◽  
Eun Bi Ma ◽  
Hunjoo Ha ◽  
Joo Young Huh
Keyword(s):  
Metabolic Regulation ◽  
Subcutaneous Fat ◽  
Diabetic Mice ◽  
Beneficial Effects ◽  
Epididymal Fat ◽  
Study Population ◽  
Exercise Induced ◽  
Type 2 Diabetic

Irisin is an exercise-induced myokine, suggested to exert beneficial effects on metabolism. However, the studies on the regulation of irisin secretion and the expression of its precursor FNDC5 have shown conflicting data. The discrepancies among previous correlation studies in humans are related to the heterogeneity of the study population. The fact that irisin is not only a myokine but also an adipokine leads to the further complexity of the role of irisin in metabolic regulation. In this study, we examined the regulation of FNDC5 expression and irisin in circulation in both type 1 and type 2 diabetic mice, and their potential relationships with metabolic parameters. In streptozotocin (STZ)-induced type 1 diabetic mice, high-fat diet (HFD)-induced obese mice and db/db mice, the circulating irisin as well as FNDC5 gene expression in subcutaneous fat was downregulated. Muscle FNDC5 expression was only significantly lower in STZ mice, and epididymal fat FNDC5 expression was unaltered. It is interesting to note that plasma irisin levels correlated positively with subcutaneous fat FNDC5 expression, but not epididymal fat or muscle. Moreover, both irisin levels and subcutaneous fat FNDC5 correlated negatively with markers of insulin resistance. These results suggest a regulatory role for subcutaneous fat-derived FNDC5/irisin in metabolic disease.

Substance P preserves pancreatic β-cells in type 1 and type 2 diabetic mice

2018 ◽  
Vol 499 (4) ◽  
pp. 960-966 ◽  
Author(s):  
Jihyun Um ◽  
Nunggum Jung ◽  
Dongjin Kim ◽  
Sanghyuk Choi ◽  
Sang-Ho Lee ◽  
...  
Keyword(s):  
Substance P ◽  
Diabetic Mice ◽  
Β Cells ◽  
Pancreatic Β Cells ◽  
Type 2 Diabetic

scholarly journals The Synergistic Effect of Valsartan and LAF237 [(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Min Shen ◽  
Dongdong Sun ◽  
Weijie Li ◽  
Bing Liu ◽  
Shenxu Wang ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Combination Treatment ◽  
Fold Change ◽  
Diabetic Mice ◽  
Dpp Iv ◽  
Vascular Oxidative Stress ◽  
To Receive ◽  
Type 2 Diabetic

Aim. To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP-IV inhibitor) on prevention against oxidative stress and inflammation injury in db/db mice aorta.Methods. Db/db mice (n=40) were randomized to receive valsartan, LAF237, valsartan plus LAF237, or saline. Oxidative stress and inflammatory reaction in diabetic mice aorta were examined.Results. Valsartan or LAF237 pretreatment significantly increased plasma GLP-1 expression, reduced apoptosis of endothelial cells isolated from diabetic mice aorta. The expression of NAD(P)H oxidase subunits also significantly decreased resulting in decreased superoxide production and ICAM-1 (fold change: valsartan : 7.5 ± 0.7,P<0.05; LAF237: 10.2 ± 1.7,P<0.05), VCAM-1 (fold change: valsartan : 5.2 ± 1.2,P<0.05; LAF237: 4.8 ± 0.6,P<0.05), and MCP-1 (fold change: valsartan: 3.2 ± 0.6, LAF237: 4.7 ± 0.8;P<0.05) expression. Moreover, the combination treatment with valsartan and LAF237 resulted in a more significant increase of GLP-1 expression. The decrease of the vascular oxidative stress and inflammation reaction was also higher than monotherapy with valsartan or LAF237.Conclusion. These data indicated that combination treatment with LAF237 and valsartan acts in a synergistic manner on vascular oxidative stress and inflammation in type 2 diabetic mice.

Differential anti-diabetic effects and mechanism of action of charantin-rich extract of Taiwanese Momordica charantia between type 1 and type 2 diabetic mice

2014 ◽  
Vol 69 ◽  
pp. 347-356 ◽  
Author(s):  
Hsien-Yi Wang ◽  
Wei-Chih Kan ◽  
Tain-Junn Cheng ◽  
Sung-Hsun Yu ◽  
Liang-Hao Chang ◽  
...  
Keyword(s):  
Mechanism Of Action ◽  
Momordica Charantia ◽  
Diabetic Mice ◽  
Type 2 Diabetic

scholarly journals Altered Dynamics in the Renal Lymphatic Circulation of Type 1 and Type 2 Diabetic Mice

2013 ◽  
Vol 46 (2) ◽  
pp. 97-104 ◽  
Author(s):  
Takanobu Uchiyama ◽  
Shunsuke Takata ◽  
Hiroyuki Ishikawa ◽  
Yoshihiko Sawa
Keyword(s):  
Diabetic Mice ◽  
Lymphatic Circulation ◽  
Type 2 Diabetic

scholarly journals The Efficacy of Red Ginseng in Type 1 and Type 2 Diabetes in Animals

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Bin Na Hong ◽  
Min Gun Ji ◽  
Tong Ho Kang
Keyword(s):  
Type 2 Diabetes ◽  
Signal Intensity ◽  
Diabetic Mice ◽  
Red Ginseng ◽  
Korean Red Ginseng ◽  
Diabetes In Animals ◽  
Brainstem Response ◽  
Type 2 Diabetic

Diabetes mellitus (DM) is one of the most modern chronic metabolic diseases in the world. Moreover, DM is one of the major causes of modern neurological diseases. In the present study, the therapeutic actions of Korean red ginseng were evaluated in type 1 and type 2 diabetic mouse models using auditory electrophysiological measurement. The comprehensive results from auditory brainstem response (ABR), auditory middle latency response (AMLR), and transient evoked otoacoustic emission (TEOAE) demonstrate auditory functional damage caused by type 1 or 2 DM. Korean red ginseng improved the hearing threshold shift, delayed latencies and signal intensity decrease in type 2 diabetic mice. Type 1 diabetic mice showed a partial improvement in decreasing amplitude and signal intensity, not significantly. We suggest that the Korean red ginseng has a more potent efficacy in hearing loss in insulin resistance type 2 diabetes than in type 1 diabetes.

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension

2014 ◽  
Vol 307 (3) ◽  
pp. F317-F325 ◽  
Author(s):  
Florian Gembardt ◽  
Christoph Bartaun ◽  
Natalia Jarzebska ◽  
Eric Mayoux ◽  
Vladimir T. Todorov ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Sglt2 Inhibitor ◽  
Western World ◽  
Diabetic Mice ◽  
Antidiabetic Therapy ◽  
Beneficial Effects ◽  
Stage Renal Disease ◽  
Early Features ◽  
Type 2 Diabetic

Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the Western world. The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors offers a new antidiabetic therapy via enhanced glucose excretion. Whether this strategy exerts beneficial effects on the development of type 2 diabetic nephropathy is still largely unclear. We investigated the effects of the specific SGLT2 inhibitor empagliflozin in BTBR.Cg-Lep<ob>/WiscJ (BTBR ob/ ob) mice, which spontaneously develop type 2 diabetic nephropathy. In the first experiment, BTBR ob/ ob mice received either a diet containing 300 ppm empagliflozin or equicaloric placebo chow for 12 wk. In the second experiment, BTBR ob/ ob mice received 1 μg·kg body wt−1·day−1 ANG II to induce arterial hypertension and were separated into the same two diet groups for 6 wk. In both experiments, empagliflozin treatment enhanced glucosuria, thereby lowering blood glucose. Independently of hypertension, empagliflozin reduced albuminuria in diabetic mice. However, empagliflozin treatment affected diabetes-related glomerular hypertrophy, markers of renal inflammation, and mesangial matrix expansion only in BTBR ob/ ob mice without hypertension. In summary, empagliflozin demonstrated significant antihyperglycemic effects, differentially ameliorating early features of diabetic nephropathy in BTBR ob/ ob mice with and without hypertension.

scholarly journals Beneficial effects of polysaccharide-rich extracts from Apocynum venetum leaves on hypoglycemic and gut microbiota in type 2 diabetic mice

2020 ◽  
Vol 127 ◽  
pp. 110182 ◽  
Author(s):  
Yuan Yuan ◽  
Jinhui Zhou ◽  
Yanfen Zheng ◽  
Zongchang Xu ◽  
Yiqiang Li ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Diabetic Mice ◽  
Beneficial Effects ◽  
Apocynum Venetum ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document